CYTR

CytRx Corporation Press Releases

$2.72
*  
0.04
1.45%
Get CYTR Alerts
*Delayed - data as of Jul. 31, 2015  -  Find a broker to begin trading CYTR now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By

CytRx Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters'' Option to Purchase Additional Shares
7/24/2015 11:00:00 AM - PR Newswire
▼-3.55 % Price Change since this news event. The Volume Ratio is 0.66.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


CytRx Announces Pricing of Public Offering of 9.1 Million Shares of Common Stock
7/21/2015 8:45:00 AM - PR Newswire
▼-5.23 % Price Change since this news event. The Volume Ratio is 24.52.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


CytRx Announces Proposed Public Offering of Common Stock
7/20/2015 4:01:00 PM - PR Newswire
▼-8.72 % Price Change since this news event. The Volume Ratio is 26.71.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




CytRx Unveils Novel LADR™ (Linker Activated Drug Release) Technology Platform
6/30/2015 9:00:00 AM - PR Newswire
▼-23.38 % Price Change since this news event. The Volume Ratio is 0.89.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi''s Sarcoma
6/29/2015 9:00:00 AM - PR Newswire
▼-27.66 % Price Change since this news event. The Volume Ratio is 1.37.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Cheryl Cohen, Former Medivation Chief Commercial Officer, Joins CytRx Board of Directors
6/24/2015 9:00:00 AM - PR Newswire
▼-32.51 % Price Change since this news event. The Volume Ratio is 0.9.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware
6/2/2015 9:00:00 AM - PR Newswire
▼-30.79 % Price Change since this news event. The Volume Ratio is 0.63.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




CytRx to Present Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting
5/27/2015 9:00:00 AM - PR Newswire
▼-30.79 % Price Change since this news event. The Volume Ratio is 1.1.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


CytRx to Present at the Jefferies 2015 Global Healthcare Conference
5/26/2015 9:00:00 AM - PR Newswire
▼-31.83 % Price Change since this news event. The Volume Ratio is 1.46.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer)
5/21/2015 9:00:00 AM - PR Newswire
▼-32.34 % Price Change since this news event. The Volume Ratio is 3.14.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day